300110 华仁药业
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)4.110-68.5127.1997.3755.633
总资产报酬率 ROA (%)1.599-31.8483.6423.3462.880
投入资产回报率 ROIC (%)1.872-35.8444.0263.8183.412

边际利润分析
销售毛利率 (%)34.14835.20242.72343.27250.582
营业利润率 (%)6.421-99.98713.80912.2569.693
息税前利润/营业总收入 (%)9.942-96.13817.95916.75413.993
净利润/营业总收入 (%)5.879-100.71511.82111.1958.588

收益指标分析
经营活动净收益/利润总额(%)107.717-6.118100.402108.010152.499
价值变动净收益/利润总额(%)3.6060.0860.366-0.673-0.577
营业外收支净额/利润总额(%)0.9390.2041.9833.579-0.693

偿债能力分析
流动比率 (X)0.7440.7661.8411.3451.200
速动比率 (X)0.5820.5601.6201.2141.093
资产负债率 (%)58.02459.92246.45549.64556.689
带息债务/全部投入资本 (%)51.37554.55641.40041.87642.782
股东权益/带息债务 (%)91.79380.605139.113129.542115.394
股东权益/负债合计 (%)68.76763.324112.26698.74274.148
利息保障倍数 (X)2.873-23.7174.6394.1443.205

营运能力分析
应收账款周转天数 (天)142.915157.117142.065160.014162.482
存货周转天数 (天)119.861134.024115.520106.255124.714